InvestorsHub Logo
Followers 31
Posts 2740
Boards Moderated 0
Alias Born 02/21/2011

Re: WilliamMunny post# 453734

Friday, 03/08/2024 4:31:31 PM

Friday, March 08, 2024 4:31:31 PM

Post# of 458189
Yes "good timing" is quoted from Dr. Missling in Q&A section of the last CC a month ago.
It wouldn't mean much but interesting. What bothers me is that he seemed not began the dialogue with FDA yet for AD trial? Even for A.A that he said he'd pursue earlier? Hope it's just mis-spoken.

Tom Bishop: Good. Where do you stand with the FDA as far as Alzheimer’s goes? I was really pleased with the news about the EMA, but what about the FDA?

Christopher Missling: Yes, it’s a great question. We actually have noticed that last night we saw the release from Eisai (dropping their Aduhelm) ......................................................... And this gives us actually probably an interesting position from a timing perspective, to prepare now a dialogue with the agency to share our data with the small molecule, which has the advantage of being easily administrable, does not have any challenging procedures. You don’t need a PET study upfront, you don’t need an MRI study upfront or during the treatment, and you can just go to the physician and be assessed and have Alzheimer disease, and the physician will say, take this capsules or pills and come back in a few weeks or months again. And so this is really a big advantage from our procedure. There’s also no requirement to have a demonstrated level of a better in the brain because in our study it was not required. We measured a better in the brain, but it was not an entry criteria.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News